Contact

For each pathology (Alzheimer’s, Parkinson’s, Huntington’s diseases and multiple sclerosis), NeurATRIS provides state-of-the-art platforms and complementary models (cells, animals) enabling the screening, the characterization, the evaluation and validation up to patients (phase II) of the most promising therapies.

NeurATRIS gives an access to powerful range of expertise and equipment through a one-stop shop covering the entire value chain of drug and biomarker discovery. 

ALZHEIMER / PARKINSON / HUNTINGTON / MULTIPLE SCLEROSIS

 

 

 

  • Neurons / astrocytes / microglia:
    -
    Treated with toxins
    -
    Infected with viral vectors (LV / AAV)
  • ESC or iPS
  • Treated with neurotoxins
  • Infected with viral vectors (LV / AAV)
  • Transgenic animals
  • Treated with neurotoxins
  • Infected with viral vectors (LV / AAV)

 

  • Characterized cohorts of patients
  • Biobanks

 

PLATFORMS

NEUROIMAGING: PET, MRI, PET-CT, PET-MRI, SPECT

COGNITION AND BEHAVIOR: Memory, language, motivation, movement, muscular strength
THERAPEUTIC APPROACHES: gene transfer, cell graft, aptamers, neurosurgery
ELECTROPHYSIOLOGY: patch recording, MEG and EEG, recordings from cell cultures, brain slices
COMPLEMENTARY EXPERTISE: ex vivo imaging, HTS, applied immunology, high-throughput real time PCR, biochemistry, proteomics, pharmacokinetics, etc.
BIOSAFETY: BSL1, 2, 3 for neurosurgery, imaging, histopathology, behavior, etc.